Bilaal.Raja
Company record

RCKT  ROCKET PHARMACEUTICALS, INC.

Trailing twelve months to 2026-06-30, as filed 2026-08-10 and not restated since.
Healthcare

Scale

Market cap
$281m
Revenue TTM
$0m
Net income TTM
$-17m
Free cash flow
$-170m
Composite score
—
Sector rank
#2650

Valuation

P / E
—
EV / EBITDA
—
EV / sales
—
FCF yield
-60.63%
Yield vs 10-yr
-11.44pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
—
EBITDA margin
—
ROE
-4.7%
ROIC
-225.2%
Revenue growth
—

Insider activity, last 90 days

Net open-market
$-0.43m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The Company will pay Cantor a cash commission of up to 3.0 % of gross proceeds from the sale of the shares pursuant to the Sales Agreement. Net Income (Loss) Per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: For the three and six months ended June 30, 2026 and 2025 , the Company included the 3,126,955 potential shares from pre-funded warrants acquired by RTW in 2023 and the 400,000 potential shares from pre-funded warrants acquired by RTW in 2024 in the basic weighted-average common shares outstanding as the warrants only require the holder to pay $ 0.01 per share upon exercise.ROCKET PHARMACEUTICALS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →